AC 105

Drug Profile

AC 105

Alternative Names: AC-105; PEG-magnesium; Pegylated-magnesium; Polyethylene-glycol-magnesium

Latest Information Update: 06 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medtronic
  • Developer Acorda Therapeutics
  • Class Magnesium compounds; Neuroprotectants; Polyethylene glycols
  • Mechanism of Action Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 01 May 2015 Acorda Therapeutics completes a phase II trial in Spinal cord injuries in USA and Canada (NCT01750684)
  • 01 Feb 2015 Acorda Therapeutics terminates its licensing agreement with Medtronic (Acorda Therapeutics 10-K, February 2015)
  • 17 Jul 2013 Phase-II clinical trials in Spinal cord injuries in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top